Viking Therapeutics, Inc.

VKTX

$32.98

$-0.45 (-1.35%)

Open

Loading chart...

IndexN/A

Market Cap3.83B

Enterprise Value3.80B

Income$-0.05B

Sales$0.00B

EmployeesN/A

P/E-7.97

P/SN/A

P/B6.20

P/C-14.22

EV/EBITDA-10.57

EV/SalesN/A

EPS (ttm)-4.14

EarningsN/A

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Volume2.87M

Shs Outstand0.12B

Change-1.35%

Dividend Est.N/A

Dividend Ex-DateN/A

Perf YTDN/A

Perf YearN/A

Perf 3YN/A

Perf 5YN/A

Perf 10YN/A

IPON/A

Today01:35PMVKTX Q2 Earnings Beat Estimates Despite Surge in R&D Costs(zacks.com)

Yesterday10:53PMViking Therapeutics, Inc. (VKTX) Q2 2026 Earnings Call Transcript(seekingalpha.com)09:04PMViking Therapeutics Q2 Earnings Call Highlights(marketbeat.com)04:05PMViking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update(prnewswire.com)08:00AM3 Biotech Stocks With Massive Upside to Buy Before August Starts(247wallst.com)

Jul 2805:00PMWall Street Says Buy the Dip in Viking Therapeutics. Here's the Bull Case(fool.com)11:10AMCan These 5 Biotech Stocks Beat Wall Street's Q2 Estimates?(zacks.com)10:31AMIs Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?(zacks.com)

Jul 2306:46PMHere's Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader Market(zacks.com)07:05AMViking Therapeutics Appoints Dorothy Gemmell to Board of Directors(prnewswire.com)

Jul 2204:05PMViking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026(prnewswire.com)

Jul 2104:41PMKuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law Firm(prnewswire.com)

Jul 1803:45PMWatch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1(fool.com)09:30AMShould You Buy Viking Therapeutics Stock on the Dip? Wall Street Is Screaming "Yes.(fool.com)

Jul 1706:46PMViking Therapeutics, Inc. (VKTX) Ascends While Market Falls: Some Facts to Note(zacks.com)11:47AMViking Therapeutics to Report Q2 Earnings: What's in Store for the Stock?(zacks.com)

Jul 1609:31PMKuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law Firm(globenewswire.com)09:31PMKuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law Firm(globenewswire.com)06:52PMViking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Know(zacks.com)

Jul 1006:46PMViking Therapeutics, Inc. (VKTX) Stock Falls Amid Market Uptick: What Investors Need to Know(zacks.com)11:50AMViking Therapeutics: Still Cheap, But Watch Double Top(seekingalpha.com)

Jul 905:34PMViking Therapeutics (VKTX) Price Forecast: Bottoming Pattern Signals Growing Strength(fxempire.com)03:00PMIs This Biotech Stock a Buy After Its Massive Rally?(fool.com)11:01AMBuyout Buzz Around VKTX Is Back: What's Fueling the Speculation?(zacks.com)08:00AM3 High Growth GLP-1 Biotech Winners to Buy in July(247wallst.com)

Jul 806:51PMWhy Viking Therapeutics, Inc. (VKTX) Dipped More Than Broader Market Today(zacks.com)

Jul 701:20PMChip Rout Drags Nasdaq 100 Lower, Oil Climbs: Stock Market Today(benzinga.com)10:36AMCRISPR Therapeutics vs. Viking Therapeutics: Is a Gene-Editing or Weight Loss Focused Stock Is a Better Buy in 2026?(fool.com)

Jul 607:35AMCRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?(fool.com)07:15AMCould This Healthcare Stock Help You Build a Real Fortune Over the Next 20 Years?(fool.com)

Insider Trading

View All

Insider

Type

Price

Value

Date

MARIANNA MANCINI

Sell

18.2K

$33.47

$610K

Jul 29, 26

GREG ZANTE

Sell

21.2K

$33.47

$710K

Jul 29, 26

BRIAN LIAN

Sell

148.5K

$33.32

$4.9M

Jul 29, 26

ZANTE GREG

Sell

21.2K

$33.47

$710K

Jul 29, 26

Lian Brian

Sell

148.5K

$33.32

$4.9M

Jul 29, 26

Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.

CEO: Brian LianEmployees: 59www.vikingtherapeutics.com

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	$260.00K	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	$-260.00K	N/A	N/A
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses	$150.92M	$100.83M	$70.36M	$55.68M	$42.66M	$32.43M	$26.16M	$19.07M
Operating Income	$-150.92M	$-100.83M	$-70.36M	$-55.68M	$-42.66M	$-32.69M	$-26.16M	$-19.07M
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Income	$-109.96M	$-85.89M	$-68.87M	$-54.99M	$-39.49M	$-25.78M	$-22.06M	$-20.58M
Net Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS (Basic)	$-1.01	$-0.91	$-0.88	$-0.70	$-0.50	$-0.36	$-0.38	$-0.79
EBITDA	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Stock Option Compensation Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Price To Earnings Ratio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Price To Sales Ratio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Shares Outstanding	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Market Capitalization	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Viking Therapeutics, Inc.

Insider Trading

Discover more

Viking Therapeutics, Inc.

Insider Trading

Discover more